Page 199 - Read Online

Saneto. J Transl Genet Genom 2020;4:384-428 I http://dx.doi.org/10.20517/jtgg.2020.40 Page 427

spectrum of mitochondrial MICU1 deficiency: a report of 13 patients. J Inherit Metab Dis 2019;43:79-83.
329. Shamseldin HE, Alasmari A, Salih MA, Samman MM, Mian SA, et al. A null mutation in MICU2 causes abnormal mitochondrial calcium
homeostasis and a severe neurodevelopmental disorder. Brain 2017;140:2806-13.
330. Choi EK, Nguyen TT, Gupta N, Iwse S, Seo YA. Functional analysis of SLC39A8 mutations and their implications for manganese
deficiency and mitochondrial disorders. Sci Rep 2018;83:3163.
331. Herzig S, Raemy E, Montessauit S, Veuthey JL, Zamboni N, et al. Identification and functional expression of the mitochondrial pyruvate
carrier. Science 2012;337:93-6.
332. Oonthonpan L, Rauckhorst AM, Gray LR, Boutron AC, Taylor EB. Two human patient mitochondrial pyruvate carrier mutations reveal
distinct molecular mechanisms of dysfunction. JCI Insight 2019;5:e126132.
333. Prajapati S, Haselbach D, Wittig S, Patel MS, Chari A, et al. Structural and functional analyses of the human PCH complex suggests a
“Division-of-Labor” mechanism by local E1 and E3 clusters. Structure 2019;27:1124-36.
334. Patel KP, O’Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical,
biochemical and genetic features in 371 patients. Mol Genet Metab 2012;105:34-43.
335. Perez-Stiles G, Ly C, Grant A, Drew AP, Yiu EM, et al. Pathologic mechanisms underlying X-linked Charcot-Marie-Tooth neuropathy
(CMTX6) in patients with pyruvate dehydrogenase kinase 3 mutation. Neurobiol Dis 2016;94:237-44.
336. Spiegel R, Pines O, Ta-Shma A, Burak E, Shaag A, et al. Infantile cerebellar-retinal degeneration associated with a mutation in
mitochondrial aconitase, ACO2. Am J Hum Genet 2012;90:518-23.
337. Fattal-Valevski A, Eliyahu H, Frenkel ND, Elmaliach G, Hausman-Kedem M, et al. Homozygous mutations, p. Pro304His, in IDH3A,
encoding isocitrate dehydrogenase subunit is associated with severe encephalopathy in infancy. Neurogenetics 2017;18:57-61.
338. Hartong DT, Dange M, McGee TL, Berson El, Dryja TP, et al. Insights from retinitis pigmentosa into the roles of isocitrate
dehydrogenases in the Krebs cycle. Nat Genet 2008;40:1230-4.
339. Kerrigan JF, Aleck KA, Tarby TJ, Bird CR, Heidenrich RA. Fumeric aciduria: clinical and imaging features. Ann Neurol 2000;47:583-8.
340. Sudarshan S, Linehan WM, Neckers L. HIF and fumerate hydratase in renal cancer. Br J Cancer 2007;96:403-7.
341. Ait-El-Mkadem S, Dayem-Quere M, Gusic M, Chaussenot A, Bannwarth S, et al. Mutations in MDH2, encoding a Krebs cycle enzyme,
cause early-onset severe encephalopathy. Am J Hum Genet 2017;100:151-9.
342. Coutelier M, Golzet C, Durr A, Gabarou F, Morais S, et al. Alteration of ornithine metabolism leads to dominant and recessive hereditary
spastic paraplegia. Brain 2015;138:2191-205.
343. Shi H, Enriquez A, Rapadas M, Martin EMMA, Wang R, et al. NAD deficiency, congenital malformations, and niacin supplementation.
N Eng J Med 2017;377:544-52.
344. Ohashi K, Kawai S, Murata K. Identification and characterization of a human mitochondrial NAD kinase. Nat Commun 2012;3:1248.
345. Tort F, Ugarteburu O, Torres M, Garcia-Villoria J, Giros M, et al. Lysine restriction and pyridoxal phosphate administration in a NADK2
patient. Pediatrics 2016;138:e20154534.
346. Pomerantz DJ, Ferdinandusse S, Cogan J, Cooper DN, Reimschisel T, et al. Clinical heterogeneity of mitochondrial NAD kinase
deficiency caused by a NADK2 start loss variant Am J Med Genet A 2018;176:692-8.
347. Kremer LS, Danhauser K, Herebian D, Ramadza DP, Piekutowska-Abramczuk D, et al. NAEX mutations disrupt the cellular NAD(P)HX
repair system and cause a lethal neurometabolic disorder of early childhood. Am J Hum Genet 2016;99:894-902.
348. Heimer G, Keratar JM, Riley LG, Balasubramaniam S, Eyal E, et al. MECR mutations cause childhood-onset dystonia and optic atrophy,
a mitochondrial fatty acid synthesis disorder. Am J Hum Genet 2016;99:1229-44.
349. Guimier A, Gordon CT, Godard F, Ravenscroft G, Oufadem M, et al. Biallelic PPA2 mutations cause sudden unexpected cardiac arrest in
infancy. Am J Hum Genet 2016;99:666-73.
350. Poon CKL, Halvorsen M, Goldstein DB, Rabin R, Cecchin F, et al. Sudden unexpected death in asymptomatic infants due to PPA2
variants. Mol Genet Genomic Med 2020;8:e1008.
351. Kennedy H, Haack TB, Hartill V, Matakovic L, Baumgartner ER, et al. Sudden cardiac death due to deficiency of the mitochondrial
inorganic pyrophosphatase PPA2. Am J Hum Genet 2016;99:674-82.
352. Sharpe AJ, McKenzie M. Mitochondrial fatty acid oxidation disorders associated with short-chain enoyl-CoA hydratase (ECHS1)
deficiency. Cells 2018;7:46.
353. Peters H, Buck N, Wanders R, Ruiter J, Waterham H, et al. ECHS1 mutations in Leigh disease: a new inborn error of metabolism
affecting valine metabolism. Brain 2014;137:2903-8.
354. Stiles AR, Ferdinandusse S, Besse A, Appadurai V, Leydiker KB, et al. Successful diagnosis of HIBCH deficiency from exome
sequencing and positive retrospective analysis of newborn screening cards in two siblings presenting with Leigh’s syndrome. Mol Genet
Metab 2015;115:161-7.
355. Barth PG, Hoffmann GF, Jaeken JJ, Lehnert W, Hanefeld F, et al. L-2-hydroxyglutaric aciduria: a novel inherited neurometabolic disease.
Ann Neurol 1992;32:66-71.
356. Steenweg ME, Jakobs C, Errami A, van Dooren SJM, Adeva Bartolome MTA, et al. An overview of L-2-Hydroxyglutarate dehydrogenase
gene (L2HGDH) variants: a genotype-phenotype study. Hum Mutat 2010;31:380-90.
357. Pop A, Struys E, Jansen EEW, Fernandez MR, Kanhai W, et al. D-2-hydroxyglutaric aciduria type I: functional analysis of D2HGH
missense variants. Hum Mutat 2019;40:975-82.
358. Lu J, Holmgren A. Thioredoxin system in cell death progression. Antioxid Redox Signal 2012;17:1738-47.
359. Holzerova E, Danhauser K, Haack TB, Dremer LS, Melcher M, et al. Human thioredoxin 2 deficiency impairs mitochondrial redox
homeostasis and causes early-onset neurodegeneration. Brain 2016;139:346-54.